FC131
Based on 1 Customer Validation
FC131 is a CXCR4 antagonist that inhibits AKT kinase activity in AML OCI-AML3 cells. D-ArgFC131, a derivative of FC131, inhibits the phosphorylation of downstream ERK1/2 and Akt, induces caspase-3 pathway-mediated apoptosis, and causes cell cycle arrest. FC131 exerts cytotoxic effects in cancer cells such as AML cells. FC131 is applicable for cancer-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.13%
- CAS. Nr.: 606968-52-9
- Formel: C36H47N11O6
- Molecular Weight:729.83
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biologische Aktivität
Beschreibung
|
CXCR4 |
Akt |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
>30 μM
Compound: 1a
|
Inhibition of [125I]SDF-1alpha binding to CXCR7 (unknown origin) expressed in CHO cell membranes incubated for 1 hr by radioligand displacement assay
Inhibition of [125I]SDF-1alpha binding to CXCR7 (unknown origin) expressed in CHO cell membranes incubated for 1 hr by radioligand displacement assay
|
[PMID: 26042340] |
| CHO | IC50 |
0.0084 μM
Compound: 3
|
Inhibition of [125I]SDF-1 binding to C-X-C chemokine receptor type 4 (CXCR4) expressed in CHO cells
Inhibition of [125I]SDF-1 binding to C-X-C chemokine receptor type 4 (CXCR4) expressed in CHO cells
|
[PMID: 15857134] |
| CHO | IC50 |
0.035 μM
Compound: 2
|
Displacement of [125I]SDF1 from human CXCR4 expressed in CHO cells
Displacement of [125I]SDF1 from human CXCR4 expressed in CHO cells
|
[PMID: 18539453] |
| HEK293 | IC50 |
0.084 μM
Compound: FC131
|
Displacement of [125I]SDF-1alpha from CXCR4 expressed in HEK293 cell membrane after 1 hr
Displacement of [125I]SDF-1alpha from CXCR4 expressed in HEK293 cell membrane after 1 hr
|
[PMID: 22352868] |
| HEK293 | IC50 |
1.2 μM
Compound: 1a
|
Inhibition of [125I]SDF-1alpha binding to CXCR4 (unknown origin) expressed in HEK293 cell membranes incubated for 1 hr by radioligand displacement assay
Inhibition of [125I]SDF-1alpha binding to CXCR4 (unknown origin) expressed in HEK293 cell membranes incubated for 1 hr by radioligand displacement assay
|
[PMID: 26042340] |
| HEK293 | IC50 |
126 nM
Compound: 2, FC131
|
Displacement of [125I]-SDF-1alpha from CXCR4 receptor expressed in HEK293 cells after 1 hr by scintillation counting
Displacement of [125I]-SDF-1alpha from CXCR4 receptor expressed in HEK293 cells after 1 hr by scintillation counting
|
[PMID: 24900333] |
| HeLa | EC50 |
21 nM
Compound: 2, FC131
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human HeLa cells assessed as inhibition of viral replication after 48 hrs by MAGI assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human HeLa cells assessed as inhibition of viral replication after 48 hrs by MAGI assay
|
[PMID: 24900333] |
| HeLa | EC50 |
21 nM
Compound: 2, FC131
|
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human HeLa cells assessed as inhibition of viral replication after 48 hrs by MAGI assay
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human HeLa cells assessed as inhibition of viral replication after 48 hrs by MAGI assay
|
[PMID: 24900333] |
| MT4 | CC50 |
>10 μM
Compound: FC131
|
Cytotoxicity against human MT4 cells assessed as reduction of cell viability
Cytotoxicity against human MT4 cells assessed as reduction of cell viability
|
[PMID: 22579418] |
| MT4 | EC50 |
0.16 μM
Compound: FC131
|
Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity
Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity
|
[PMID: 22579418] |
In Vitro
FC131 (0.5-4.0 μM; 48 h) combined with Panobinostat (HY-10224) synergistically induces apoptosis in human AML OCI-AML3 cells, and the corresponding combination index value is less than 1.0[1].
FC131 (2 μM plus 50 nM Panobinostat; 48 h) induces significantly higher lethality in primary human AML cells than in normal human CD34+ bone marrow progenitor cells[1].
FC131 (1 μM; 24 h) partially inhibits AKT kinase activity in human AML OCI-AML3 cells, and combined treatment with 50 nM Panobinostat enhances this AKT kinase inhibitory effect without altering the Panobinostat-mediated reduction in the levels of CXCR4, GRK3 and downstream signaling proteins[1].
FC131 (100 nM; 6 h) inhibits the activity of the GH promoter in GH3 rat pituitary tumor cells, reducing luciferase activity to 0.3-fold that of the control group[2].
FC131 (10-100 nM; 6 days) slightly inhibits the proliferation of GH3 rat pituitary tumor cells[2].
FC131 (1 nM-100 μM; 10 min pre-incubation, 90 min co-incubation with CXCL12) potently inhibits CXCL12-mediated IP accumulation in COS-7 cells expressing wild-type CXCR4, with an IC50 of 0.40 μM; the H113A, D171N and D262N mutations significantly reduce its potency, while the W94A and D97A mutations enhance its potency[3].
FC131 (1 nM-100 μM; 3 h) binds to wild-type CXCR4 expressed in COS-7 cells, with an IC50 of 0.76 μM; the H113A, Y116A, D171N and D262N mutations significantly reduce its binding affinity, the H281A, D187A and E288A mutations moderately reduce its binding affinity, while the W94A and D97A mutations increase its binding affinity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human AML OCI-AML3 cell line
-
Concentration:1 μM
50 nM Panobinostat -
Incubation Time:24 h
-
Result:Inhibied AKT kinase activity in human AML OCI-AML3 cells, and combined treatment with 50 nM Panobinostat enhances this AKT kinase inhibitory effect without altering the Panobinostat-mediated reduction in the levels of CXCR4, GRK3 and downstream signaling proteins.
-
Cell Line:GH3 rat pituitary tumor cells
-
Concentration:10, 100 nM
-
Incubation Time:6 days (twice-daily treatment)
-
Result:Reduced GH3 cell number to ~90% of the control at both 10 nM and 100 nM.
Chemical Information
-
CAS. Nr. 606968-52-9
-
Appearance Solid
-
Molecular Weight 729.83
-
Formel C36H47N11O6
-
Color White to off-white
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (137.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Mandawat A, et al. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood. 2010 Dec 09;116(24):5306-15. [Content Brief]
[2]. Kim JM, et al. The cyclic pentapeptide d-Arg3FC131, a CXCR4 antagonist, induces apoptosis of somatotrope tumor and inhibits tumor growth in nude mice. Endocrinology. 2011 Feb;152(2):536-44. [Content Brief]
[3]. Thiele S, et al. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. British journal of pharmacology. 2014 Dec;171(23):5313-29. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3702 mL | 6.8509 mL | 13.7018 mL | 34.2546 mL |
| 5 mM | 0.2740 mL | 1.3702 mL | 2.7404 mL | 6.8509 mL | |
| 10 mM | 0.1370 mL | 0.6851 mL | 1.3702 mL | 3.4255 mL | |
| 15 mM | 0.0913 mL | 0.4567 mL | 0.9135 mL | 2.2836 mL | |
| 20 mM | 0.0685 mL | 0.3425 mL | 0.6851 mL | 1.7127 mL | |
| 25 mM | 0.0548 mL | 0.2740 mL | 0.5481 mL | 1.3702 mL | |
| 30 mM | 0.0457 mL | 0.2284 mL | 0.4567 mL | 1.1418 mL | |
| 40 mM | 0.0343 mL | 0.1713 mL | 0.3425 mL | 0.8564 mL | |
| 50 mM | 0.0274 mL | 0.1370 mL | 0.2740 mL | 0.6851 mL | |
| 60 mM | 0.0228 mL | 0.1142 mL | 0.2284 mL | 0.5709 mL | |
| 80 mM | 0.0171 mL | 0.0856 mL | 0.1713 mL | 0.4282 mL | |
| 100 mM | 0.0137 mL | 0.0685 mL | 0.1370 mL | 0.3425 mL |